Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021Business Wire • 11/15/21
Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core InhibitorBusiness Wire • 11/12/21
4 Small Drug Stocks That Hold Promise Despite Industry ChallengesZacks Investment Research • 10/27/21
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021Business Wire • 10/19/21
Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?Zacks Investment Research • 10/08/21
New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and TreatmentBusiness Wire • 10/06/21
Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual ConferenceBusiness Wire • 10/05/21
Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021Business Wire • 10/01/21
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA DestabilizerBusiness Wire • 08/16/21
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/21
Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ETBusiness Wire • 08/05/21
Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19Business Wire • 08/05/21
Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021Business Wire • 07/29/21
Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.Business Wire • 07/14/21
Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™Business Wire • 06/23/21
Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV PatientsBusiness Wire • 06/22/21
Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the LiverBusiness Wire • 06/03/21
Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/11/21
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21